Progenics Pharmaceuticals (PGNX) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.08 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.11. The company posted revenue of $8.48 million in the period, compared to analysts expectations of $6.31 million. The company’s revenue was up 337.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Progenics Pharmaceuticals closed down -0.18 points or -3.08% at $5.66 with 15,22,465 shares getting traded on Tusday. Post opening the session at $5.8, the shares hit an intraday low of $5.58 and an intraday high of $5.91 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Apr 22, 2016, Paul J Maddon (director) purchased 5,000 shares at $4.90 per share price. According to the SEC, on Jun 15, 2015, Robert J Israel (Executive Vice President, Medi) sold 2,000 shares at $6.83 per share price.
Progenics Pharmaceuticals Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma a rare tumor found in the adrenal glands and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor a cure for opioid-induced constipation (OIC).